Home > Compound List > Product Information
Levonorgestrel_Molecular_structure_CAS_797-63-7)
Click picture or here to close

Levonorgestrel

Catalog No. DB00367 Name DrugBank
CAS Number 797-63-7 Website http://www.ualberta.ca/
M. F. C21H28O2 Telephone (780) 492-3111
M. W. 312.44582 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 251

SYNONYMS

IUPAC name
(1S,2R,10R,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxytetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
IUPAC Traditional name
norgestrel
Brand Name
Microgyn
Nordet
Follistrel
72-HOURS
Monofeme 28
Ovranette
Microgynon 21
Microgynon 30 Ed
Microgynon Cd
Minivlar 30
Mirena
Norplant
Norplant 2
Norplant II
Triagynon
NorLevo
Jadelle
Levora-21
Levora-28
Logynon Ed
Microgest Ed
Microgynon 28
Microval
Neogynon 21
Nordette
Nordette 21
Ovral-Lo
Ovrette
Plan B
Rigevidon 21+7
Tri-Levlen
Triciclor
Trifeme 28
Trigoa
Trinordiol 21
Trivora
Postinor-2
Levlen
Levlen Ed
Malloside
Microlution
Nordette 28
Stediril 30
Tri-Levlen 21
Trinordiol 28
Levonelle
Levonova
Synonyms
SOH-075
Levonorgestrelum [INN-Latin]

DATABASE IDS

PubChem SID 46508082
PubChem CID 13109
CAS Number 797-63-7

PROPERTIES

Hydrophobicity(logP) 3.8
Solubility 2.05 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description A synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or (+-)-isomer (norgestrel). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. It is usually supplied in a racemic mixture (Norgestrel, 6533-00-2). Only the levonorgestrel isomer is active.
Indication For the treatment of menopausal and postmenopausal disorders and alone or in combination with other hormones as an oral contraceptive.
Pharmacology Levonorgestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Levonorgestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.
Toxicity LD50 >5000 mg/kg (orally in rats)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic
Absorption Levonorgestrel is not subjected to a "first-pass" effect and is virtually 100% bioavailable.
Protein Binding 55%
Elimination About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.
Distribution * 260 L [Healthy Female Volunteers under Fasting Conditions]
* 1.8 L/kg
Clearance * 7.7 +/- 2.7 L/h [Healthy Female Volunteers under Fasting Conditions]
References
Edgren RA, Stanczyk FZ: Nomenclature of the gonane progestins. Contraception. 1999 Dec;60(6):313. [Pubmed]
Sitruk-Ware R: New progestagens for contraceptive use. Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES

  • Sitruk-Ware R: New progestagens for contraceptive use. Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16. Pubmed
  • Edgren RA, Stanczyk FZ: Nomenclature of the gonane progestins. Contraception. 1999 Dec;60(6):313. Pubmed